Anton Kruger

Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s Lymphoma

John Radford, Tim Illidge, Nicholas Counsell et al. · New England Journal of Medicine · 2015 · 734 citations · Full text

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles

David Cunningham, Eliza A. Hawkes, Andrew Jack et al. · The Lancet · 2013 · 546 citations · Full text

Alemtuzumab in Combination With Methylprednisolone Is a Highly Effective Induction Regimen for Patients With Chronic Lymphocytic Leukemia and Deletion of <i>TP53</i>: Final Results of the National Cancer Research Institute CLL206 Trial

Andrew R. Pettitt, Richard E. Jackson, Stacey Carruthers et al. · Journal of Clinical Oncology · 2012 · 164 citations

Establishing the incidence of myelodysplastic syndrome

Patrick Williamson, Anton Kruger, Peggy Reynolds et al. · British Journal of Haematology · 1994 · 160 citations

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

Judith Trotman, Sally F. Barrington, David Belada et al. · The Lancet Oncology · 2018 · 152 citations · Full text

Lymphoid Neoplasia, End-of-induction Pet Response, Medicine +7